Is an Lp(a) Blood Test Worth Getting?

Photo by Trần Văn Sơn on Unsplash

By The Longevity Dose Editorial Team · Evidence-reviewed · Last updated July 2026

The Lp(a) blood test is worth getting at least once in your lifetime, and most cardiologists and longevity physicians now agree on that. Lipoprotein(a), pronounced “LP little a,” is a genetically determined cardiovascular risk factor that roughly 1 in 5 people carry at dangerously elevated levels. Most of them have no idea. Your doctor has likely never mentioned it. Standard cholesterol panels don’t include it. And unlike LDL cholesterol, you can’t diet or exercise your way out of a high number. That combination — silent, inherited, and largely unaddressed by conventional medicine — is exactly why the Lp(a) blood test has become one of the most debated topics in longevity biomarker tracking right now.

What Exactly Is Lp(a) and Why Does It Matter?

Lp(a) is a modified LDL particle. It has a standard LDL cholesterol core, but it also carries a protein called apolipoprotein(a), or apo(a), attached to it. That extra protein is what makes Lp(a) uniquely dangerous in two distinct ways.

First, it promotes atherosclerosis, the buildup of plaque in artery walls. This is the same mechanism that drives standard LDL-related heart disease. But Lp(a)’s apo(a) component also structurally resembles plasminogen, a protein your body uses to dissolve blood clots. Because of this similarity, Lp(a) interferes with your natural clot-clearing process.

A 2026 study published in the Journal of Thrombosis and Haemostasis (PMID 41177455) examined exactly this mechanism. Evidence from that study indicates Lp(a) prolongs clot lysis times by affecting clot formation rate and fibrin structure — meaning clots that form in people with high Lp(a) take longer to dissolve. That’s a direct pathway to heart attack and stroke that has nothing to do with plaque buildup. Two separate mechanisms, one particle.

Lp(a) also drives calcification of the aortic valve, a condition called aortic stenosis that often requires open-heart surgery to correct. No other standard lipid marker is as strongly linked to this specific outcome.

Bottom line: Lp(a) is a two-pronged cardiovascular threat. It accelerates arterial plaque AND impairs clot dissolution. Most people with high levels have never been tested.

Who Should Get an Lp(a) Blood Test?

The short answer: almost everyone. The European Society of Cardiology, the American Heart Association, and the European Atherosclerosis Society have all issued guidance supporting at least one Lp(a) measurement in all adults. In practice, it almost never happens.

A 2026 review in Current Opinion in Lipidology (PMID 41631372) put it plainly. Despite broad guideline support for universal one-time testing, Lp(a) measurement remains rare in clinical practice. The same review explored machine learning tools to help identify high-risk patients who should be prioritized for testing, precisely because routine screening hasn’t taken hold.

That said, certain groups carry higher urgency:

• Anyone with a family history of early heart disease (before age 55 in men, before age 65 in women)
• Anyone who has already had a heart attack, stroke, or aortic stenosis with no obvious explanation
• Anyone whose LDL or ApoB is already elevated (see our full breakdown of ApoB optimal ranges)
• People of South Asian or African descent, who statistically have higher average Lp(a) levels
• Anyone currently on a statin whose cardiovascular risk still feels unexplained

But if you’re serious about longevity and you’ve never tested, the honest answer is that the test costs under $50 in most cases and you only need to do it once. The risk-to-reward ratio is hard to argue with.

Bottom line: Broadly, all adults should test once. People with family history of early cardiac events or unexplained cardiovascular disease should prioritize it immediately.

What Do Lp(a) Levels Actually Mean? The Numbers Explained

Labs measure Lp(a) in two different units, which causes a lot of confusion. Some report in mg/dL, others in nmol/L. They’re not directly interchangeable, and your result depends on which assay your lab uses.

Dr. Peter Attia, whose Medicine 3.0 framework has become a reference point for serious longevity thinking, considers Lp(a) above 50 mg/dL a meaningful risk signal that should change how aggressively you target other modifiable risk factors like LDL, blood pressure, and inflammation. His book Outlive: The Science and Art of Longevity gives a clear, practical framework for understanding where Lp(a) fits into a broader cardiovascular risk picture. It’s the best single resource for making sense of your own lab numbers in context.

A 2026 study in the Journal of Atherosclerosis and Thrombosis (PMID 41371705) looked at Lp(a) levels in Japanese patients and found that elevated Lp(a), when combined with other cardiovascular risk scores, predicted the presence of high-risk arterial plaque above and beyond standard risk calculations. This matters because it confirms that Lp(a) adds independent predictive value, even in populations where average Lp(a) levels differ from Western cohorts.

Bottom line: Above 50 mg/dL (or 125 nmol/L) is the broadly accepted threshold for elevated risk. Above 100 mg/dL is considered very high risk and warrants active risk-reduction strategies.

Can You Lower Your Lp(a) With Lifestyle or Supplements?

This is the hard part. The honest answer is: not meaningfully, with current tools.

Lp(a) levels are 80-90% genetically determined. Statins, the most widely prescribed cardiovascular drugs, don’t lower Lp(a) and may actually raise it slightly in some people. A 2026 meta-analysis published in Acta Cardiologica (PMID 41841426) confirmed that Lp(a) is a proatherogenic lipoprotein that is minimally responsive to statins or lifestyle changes.

That said, here’s what the evidence suggests might help at the margins:

• Niacin (high-dose): Can reduce Lp(a) by 20-30% in some studies, but clinical trials haven’t shown that this translates to fewer cardiovascular events. Side effects at therapeutic doses are significant.
• PCSK9 inhibitors (like evolocumab or alirocumab): Reduce Lp(a) by roughly 20-25% as a secondary effect, on top of their primary LDL-lowering action.
• Lipoprotein apheresis: A dialysis-like procedure that physically removes Lp(a) from the blood. It works, but it’s invasive, expensive, and only available to very high-risk patients.
• Aspirin: Sometimes discussed because of Lp(a)’s clotting effects, but the evidence for routine use is mixed and it carries its own risks.

What genuinely doesn’t move Lp(a): diet, exercise, omega-3s, or standard statin therapy. If you’ve read our guide on the omega-3 index, you know omega-3s are excellent for cardiovascular health through other pathways, but Lp(a) reduction isn’t one of them.

What’s Coming: RNA-Targeting Therapies

This is where the picture gets genuinely exciting. Two classes of drugs targeting Lp(a) at the genetic level are in late-stage clinical trials as of 2026. Pelacarsen (an antisense oligonucleotide) and olpasiran (a small interfering RNA, or siRNA) both reduce Lp(a) by 70-90% in human trials. We’re waiting on cardiovascular outcomes data to confirm whether that dramatic reduction translates to fewer heart attacks and strokes. Results from the major outcomes trials are expected by 2026-2027.

Separately, a 2026 randomized controlled trial in Nature Medicine (PMID 41760952) tested obicetrapib, a CETP inhibitor, in patients with familial hypercholesterolemia, a condition that often co-exists with elevated Lp(a). While obicetrapib’s primary target is LDL reduction, this class of drugs also shows secondary effects on Lp(a) that researchers are actively studying.

Knowing your Lp(a) number now means you’re positioned to have a real conversation with your doctor the moment these therapies reach approval.

Bottom line: Current lifestyle tools barely move Lp(a). New RNA-targeting drugs may change this dramatically within 1-2 years. That’s a strong argument for testing now, not later.

How to Actually Get an Lp(a) Blood Test in 2026

Getting tested is easier than most people think. Here are your practical options:

• Ask your doctor directly. Simply request an Lp(a) test at your next physical. Most labs that process standard lipid panels can run it. The challenge is that many general practitioners don’t order it routinely, so you may need to advocate for yourself.
• Direct-to-consumer lab testing. Services like Ulta Lab Tests, Any Lab Test Now, or Quest Diagnostics direct pay allow you to order an Lp(a) panel without a doctor’s order. Costs typically range from $30-$60 out of pocket.
• Cardiologist or preventive medicine specialist. If you have any cardiovascular risk factors, a preventive cardiologist will almost certainly include Lp(a) in a comprehensive workup.

One important note: you only need to test once. Because Lp(a) is genetically set, repeating the test doesn’t add meaningful information unless you’re enrolled in a clinical trial or monitoring a specific therapeutic intervention. This is fundamentally different from ApoB or blood pressure, which you’d track regularly over time.

Lp(a) testing fits naturally into a broader biomarker strategy. If you’re building out a full longevity panel, pairing Lp(a) with ApoB, fasting insulin, hs-CRP, and other markers gives you a far more complete cardiovascular risk picture than standard cholesterol alone.

Bottom line: Order an Lp(a) test once, either through your doctor or a direct-to-consumer lab service. It’s cheap, requires no special preparation, and you’ll never need to repeat it unless you’re on a targeted therapy.

The Verdict: Is the Lp(a) Blood Test Worth It?

Yes, without reservation. The Lp(a) blood test is one of the highest-value single tests you can add to your longevity toolkit, precisely because it gives you information that nothing else does, at a cost that’s trivial.

If your number is low, you’ve permanently ruled out one of the most underappreciated cardiovascular risk factors. That’s genuinely good news worth knowing.

If your number is elevated, you now have actionable information. You can work with your doctor to be more aggressive about every other modifiable risk factor. You can monitor the emerging drug therapies closely. And you can stop assuming that “normal cholesterol” means low cardiovascular risk, because for 1 in 5 people, it doesn’t.

Lp(a) is one of medicine’s most glaring blind spots. The test exists. The evidence for testing is strong. The only reason most people haven’t done it is that no one told them to. Consider this your notice.

Affiliate Disclosure: The Longevity Dose may earn a small commission if you purchase through the links below, at no additional cost to you. We only recommend products we genuinely believe in. Learn more.

Frequently Asked Questions

What is the Lp(a) blood test measuring?

The Lp(a) blood test measures the concentration of lipoprotein(a) in your blood, expressed in either mg/dL or nmol/L. Lp(a) is a modified LDL particle with an additional protein called apolipoprotein(a) attached to it. Elevated levels are independently associated with increased risk of heart attack, stroke, and aortic valve disease.

Do I need to fast before an Lp(a) test?

No. Unlike fasting glucose or triglycerides, Lp(a) levels are not meaningfully affected by recent food intake. You can take the test at any time of day without fasting. This makes it easier to add to any routine blood draw.

What Lp(a) level is considered high?

Most guidelines set the high-risk threshold at 50 mg/dL or 125 nmol/L. Above 100 mg/dL (roughly 250 nmol/L) is considered very high risk. Approximately 20% of the global population falls above the 50 mg/dL threshold, though the exact proportion varies by ethnicity.

Can I lower my Lp(a) with diet and exercise?

Not meaningfully. Lp(a) is 80-90% determined by genetics and doesn’t respond to standard lifestyle interventions. Statins do not lower it and may slightly raise it. New RNA-targeting drugs currently in late-stage clinical trials as of 2026 can reduce Lp(a) by 70-90%, but they are not yet approved for general use.

How often should I test my Lp(a)?

For most people, once in a lifetime is sufficient. Because Lp(a) is genetically set, it stays relatively stable throughout adulthood. Repeat testing is only warranted if you’re participating in a clinical trial, monitoring the effect of a targeted drug therapy, or if your initial result was borderline and you want confirmation.

Is the Lp(a) blood test covered by insurance?

Coverage varies by insurer and country. In the United States, it’s often covered when there’s a documented family history of cardiovascular disease or when a physician documents medical necessity. If it’s not covered, direct-to-consumer lab services typically offer it for $30-$60 out of pocket, making it accessible regardless of insurance status.